Stemline Therapeutics (STML) Misses Q4 EPS by 2c

Stemline Therapeutics (NASDAQ: STML) reported Q4 EPS of ($0.53), $0.02 worse than the analyst estimate of ($0.51).

Stemline ended the fourth quarter of 2014 with $58.6 million in cash, cash equivalents and investments, as compared to $65.0 million as of September 30, 2014. In January 2015, the Company completed an equity offering raising $68 million in gross proceeds, bringing our cash position to approximately $120 million.

For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15